Antiviral Activity of Hederasaponin B from Hedera helix against Enterovirus 71 Subgenotypes C3 and C4a

• Published in: Biomolecules & therapeutics Vol. 22; no. 1; pp. 41 - 46
• Main Authors: Song, JaeHyoung, Yeo, Sang-Gu, Hong, Eun-Hye, Lee, Bo-Ra, Kim, Jin-Won, Kim, JeongHoon, Jeong, HyeonGun, Kwon, YongSoo, Kim, HyunPyo, Lee, SangWon, Park, Jae-Hak, Ko, Hyun-Jeong
• Format: Journal Article
• Language: Korean
• Published: 한국응용약물학회 30.01.2014
• Subjects: Antiviral activity; Enterovirus 71; Hand foot and mouth disease; Hedera helix; Hederasaponin B; Enterovirus 71; Hederasaponin B; Hedera helix; Hand foot and mouth disease; Antiviral activity
• ISSN: 1976-9148; 2005-4483

Enterovirus 71 (EV71) is the predominant cause of hand, foot and mouth disease (HFMD). The antiviral activity of hederasaponin B from Hedera helix against EV71 subgenotypes C3 and C4a was evaluated in vero cells. In the current study, the antiviral activity of hederasaponin B against EV71 C3 and C4a was determined by cytopathic effect (CPE) reduction method and western blot assay. Our results demonstrated that hederasaponin B and 30% ethanol extract of Hedera helix containing hederasaponin B showed significant antiviral activity against EV71 subgenotypes C3 and C4a by reducing the formation of a visible CPE. Hederasaponin B also inhibited the viral VP2 protein expression, suggesting the inhibition of viral capsid protein synthesis.These results suggest that hederasaponin B and Hedera helix extract containing hederasaponin B can be novel drug candidates with broad-spectrum antiviral activity against various subgenotypes of EV71.